Multicomponent Intravaginal Ring with Segmented Polymeric Matrices
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing intravaginal ring systems lack improvements in polymeric matrix composition for enhanced clinical use and economic manufacturing without compromising clinical efficacy, particularly for the bimodal release of contraceptive and bioactive agents with antiviral and antiretroviral activities, and there is a need for effective delivery systems for HIV prevention and treatment.
Innovation Solution
A multicomponent microbicidal contraceptive intravaginal ringed-mesh device with a silicone ring matrix and polyester fibrous mesh, featuring a polymeric coating for independent controlled release of contraceptive and bioactive agents, including antiretroviral drugs, and using hydrophilic and hydrophobic polymers for single-mode or bimodal release, along with a process involving chemical treatment and spray-coating for enhanced bioavailability and spermicidal properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If a single polymeric matrix is used in the intravaginal ring, then the device structure is simple and manufacturing is easier, but the controlled release profile of multiple bioactive agents cannot be optimized
Solution Approach 1:
The intravaginal ring is divided into multiple polymeric matrix layers, each containing different bioactive agents with distinct release characteristics. This segmentation allows independent optimization of release profiles for contraceptive agents, antiviral agents, and antifungal agents while maintaining overall device functionality.
Solution Approach 2:
The device uses composite polymeric matrices with different polymer compositions to achieve differential release rates of various bioactive agents. The composite structure enables simultaneous delivery of multiple agents with optimized pharmacokinetics without requiring separate devices.
2Reliability
If the polymeric matrix composition is enhanced for improved clinical efficacy, then the release control of bioactive agents is improved, but the manufacturing complexity and cost increase
Solution Approach 1:
Different regions of the polymeric matrix are formulated with specific local compositions optimized for their intended function. The matrix containing antiviral agents has different polymer characteristics than the matrix containing antifungal agents, allowing each region to perform its specific clinical function optimally.
Solution Approach 2:
The polymeric matrix parameters such as crosslinking density, porosity, and hydrophilicity are adjusted to control the release rate of different bioactive agents. By changing these parameters in different matrix regions, the device achieves optimized clinical efficacy for multiple agents simultaneously.
3Adaptability or versatility
If multiple bioactive agents are released from a single matrix, then the device functionality is enhanced, but the release profiles of individual agents cannot be independently optimized
Solution Approach 1:
The device is segmented into multiple functional matrices, each responsible for releasing specific bioactive agents with independently optimized release profiles. This segmentation enables precise control over the release kinetics of contraceptive agents, antiviral agents, and antifungal agents separately.
Solution Approach 2:
Different polymeric matrices act as intermediaries between the bioactive agents and the vaginal environment. Each polymer matrix is selected and formulated to provide the appropriate release rate and duration for its associated bioactive agent, enabling independent optimization of release profiles.
4Duration of action of stationary object
If the ring system is designed for extended duration of action, then the frequency of application is reduced, but the complexity of controlling release over time increases
Solution Approach 1:
The polymeric matrices are designed to release bioactive agents in periodic or sustained patterns over extended periods. The release mechanisms utilize polymer degradation, diffusion, and erosion processes that naturally provide time-dependent release profiles without requiring complex active control systems.
Solution Approach 2:
The device maintains continuous release of bioactive agents throughout the retention period in the vagina. The polymeric matrices are formulated to provide sustained delivery of multiple agents simultaneously, ensuring continuous therapeutic and contraceptive protection without interruption.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device achieves effective, controlled release of bioactive agents, providing contraception, antimicrobial, and antiretroviral protection, enhancing clinical efficacy and commercial viability while addressing the limitations of previous systems in HIV prevention and treatment.
Implementation Method 1
controlled release of at least one bioactive agent
Implementation Method 2
absorbable coating to provide three modes of controlling the release
Implementation Method 3
use of a hydrophilic polymer and a relatively hydrophobic polymer
Implementation Method 4
use of a hydrophilic polymer and a relatively hydrophobic polymer
Implementation Method 5
process involving chemical treatment and spray-coating for enhanced bioavailability
Data Source
AI summary
Intravaginal ring devices have multicomponent drug releasing substrates loaded with at least one bioactive agent and designed to effect contraception and/or provide means to treat and/or prevent diseases caused by infectious bacteria, fungi, virus, and retroviruses, without compromising the primary function of normally occurring, useful vaginal microflora in female patients.